Roche Diagnostics Intends to Form Strategic Partnership with CapitalBio

Roche Diagnostics (Basel, Switzerland) and China's premier biochip development company, CapitalBio (Beijing, China) announced their intention to initiate a strategic partnership targeting molecular diagnostic applications and the development of technologies to fill the unmet needs of researchers worldwide.

The new development builds on the genomics and diagnostics expertise of the two companies and it will focus on furthering microarray technologies and complementary products for molecular diagnostic applications.

The partnership plans to focus initially on the research and development of instruments and products to enhance and automate the Roche NimbleGen microarray workflow and the application of this workflow in preventive and personalized diagnostics.

Special focus shall be placed on cooperation in education on the benefits and use of molecular diagnostics that exploit novel technologies involving microarrays and their related products, and next-generation sequencing in both the greater China and international markets. The partnership also plans to establish educational facilities across China for molecular R&D and the application of clinical molecular diagnostics.

"CapitalBio and Roche offer a large number of complementary skills and interests which can be well served through the harnessing of the capabilities of both companies for product research and development, manufacturing, marketing, and distribution in China and for international markets,” said Professor Jing Cheng, CEO of CapitalBio.

Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is a world leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

CapitalBio Corporation is China's leading developer and marketer of diagnostic biochips, microarray related instruments, and microarray services. Its range of LuxScan laser confocal microarray scanners, microarray spotters, and related microarray workflow instruments are used widely in many countries. Its active biochips for cell biology studies and dedicated software for data analysis and biomedical data management are also being used increasingly for clinical studies, including oncology studies.

Related Links:
Roche
CapitalBio